Audacity R4 Medicines Fund

Audacity R4 Pharmaceutical Fund appears to be a healthcare-focused investment vehicle associated with the Audacity organization rather than an operating drug-development biotech company. Public references tie the fund to Barbara Handelin and describe it as part of a proposed new biopharmaceutical business model intended to prioritize medical value ahead of financial returns, with a focus on rare and orphan diseases. Available evidence suggests the fund is linked to Audacity Therapeutics, a public benefit corporation, and sits adjacent to efforts in rare-disease therapy development and impact-oriented pharmaceutical investing. There is not enough public evidence to support a conventional therapeutic pipeline, modality set, or company-stage classification for the fund itself.